The phase I trial (NCT02864290) testing AGS62P1, an anti-FLT3 antibody-amberstatin 269 (an microtubule disrupting agent), in R/R adult AML has been closed for lack of efficacy [123]. The gene discussed is FLT3; the disease is acute myeloid leukemia.